Pacific Biosciences of California, Inc.

NASDAQ:PACB

Medical - Devices

Healthcare
$1.83 +3.17%

+$0.04 today

Market cap
$571.39M
Beta
2.32
P/E (TTM)
-3.3
EPS (TTM)
-$0.42
52W Low $1.09High $2.73

Volume 15.30M

Average 6.06M

PACB Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Pacific Biosciences of California, Inc.NASDAQ: PACB

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns positive

Q1 FY2026 gross profit was $12.84M, compared with -$1.37M a year earlier. Trailing-twelve-month gross profit was $59.34M. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Gross profit amounted to 31.7% of revenue in FY2025, up 7.5 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near $12.84M or moves back toward the trailing-twelve-month quarterly average of $14.84M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.84M-23.3% QoQ
Last fiscal yearDec 2025
$50.67M+35.9% YoY
LTMMar 2026
$59.34M+140.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1036.6%——
1 year+35.9%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
50.67M USD
Year-over-year change
+35.9%
4-year CAGR
-3.7%

Gross Profit vs competitors

How PACB compares with its peers on the latest reported figures

  • PACB's LTM Mar 2026 gross profit of $59.34M is the 2nd highest of the 3 companies compared; the peer median is $1.5B.
  • Its year-over-year change of +140.9% is the highest of 3, against a peer median of -27.4%.
  • Gross profit amounts to 37.1% of revenue for PACB, versus a peer median of 53.4%.
PACB Competitors Peer median
Gross Profit for PACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ILMNIllumina, Inc.LTM Jun 2026$3B +4.4%-0.9%66.8%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$59.34M +140.9%+1.1%37.1%
QSIQuantum-Si incorporatedLTM Mar 2026$741K -59.2%—40.0%
Peer median (excluding PACB) $1.5B-27.4%-0.9%53.4%

Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.51M128.3M200.52M154.01M160.01M
Cost of Revenue71.65M79.27M147.74M116.73M109.33M
Gross Profit58.86M49.04M52.78M37.28M50.67M
Gross Margin45.1%38.2%26.3%24.2%31.7%
Research & Development112.9M193M187.17M134.92M97.31M
Selling, General & Admin124.12M160.85M169.82M175.02M141.49M
Operating Expenses269.3M356.23M387.25M511.6M608.24M
Depreciation & Amortization11.59M17.32M32.69M53.35M504.91M
EBITDA(250.76M)(282.24M)(271.13M)(242.77M)(34.2M)
EBITDA Margin-192.1%-220.0%-135.2%-157.6%-21.4%
Operating Income(210.44M)(307.2M)(334.47M)(474.31M)(557.56M)
Operating Margin-161.2%-239.4%-166.8%-308.0%-348.5%
Interest Income00000
Interest Expense12.53M14.69M14.34M13.41M6.95M
Other Income / Expenses(64.44M)(7.05M)16.31M164.78M11.5M
Income Before Tax(274.87M)(314.25M)(318.16M)(309.54M)(546.06M)
Pre-Tax Margin-210.6%-244.9%-158.7%-201.0%-341.3%
Income Tax Expense(93.65M)0(11.42M)316K318K
Net Income(181.22M)(314.25M)(306.74M)(309.85M)(546.38M)
Net Margin-138.9%-244.9%-153.0%-201.2%-341.5%
EPS (Basic)(0.89)(1.40)(1.21)(1.13)(1.82)
EPS (Diluted)(0.89)(1.40)(1.21)(1.07)(1.82)
Weighted Avg Shares203.62M224.55M253.63M274.49M299.96M
Weighted Avg Shares (Diluted)204.14M224.55M253.63M288.37M299.96M

Pacific Biosciences of California, Inc.

NASDAQ:PACB

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.